These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34478146)

  • 1. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins.
    Chung S; Lin YL; Nguyen V; Liu C
    Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
    Chung S; Lin YL; Nguyen V; Kamen L; Zheng K; Vora B; Song A
    J Immunol Methods; 2018 Nov; 462():101-105. PubMed ID: 30030147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
    Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
    MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Chung S; Nguyen V; Lin YL; Lafrance-Vanasse J; Scales SJ; Lin K; Deng R; Williams K; Sperinde G; Li JJ; Zheng K; Sukumaran S; Tesar D; Ernst JA; Fischer S; Lazar GA; Prabhu S; Song A
    MAbs; 2019 Jul; 11(5):942-955. PubMed ID: 30982394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and screening of IgG binding to the neonatal Fc receptor.
    Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
    MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of FcRn binding assays to guide mAb development.
    Datta-Mannan A; Wroblewski VJ
    Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular Neonatal Fc Receptor Recycling Efficiencies can Differentiate Target-Independent Clearance Mechanisms of Monoclonal Antibodies.
    Bryniarski MA; Tuhin MTH; Acker TM; Wakefield DL; Sethaputra PG; Cook KD; Soto M; Ponce M; Primack R; Jagarapu A; LaGory EL; Conner KP
    J Pharm Sci; 2024 Sep; 113(9):2879-2894. PubMed ID: 38906252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.
    Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
    Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
    J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method.
    Müller T; Tasser C; Tesar M; Fucek I; Schniegler-Mattox U; Koch J; Ellwanger K
    MAbs; 2023; 15(1):2245519. PubMed ID: 37599441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.
    Suzuki T; Hashii N; Tada M; Ishii-Watabe A
    MAbs; 2021; 13(1):1923366. PubMed ID: 34030575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.